Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Curis Q3 2026 Results: Net Loss of $8.12M, Loss Widens

Curis, Inc. reported a total stockholders' equity of $2.55 million as of September 30, 2026, a decrease from $5.46 million at the end of 2025. The company continues to incur substantial losses, with an accumulated deficit reaching $1.29 billion, and management has identified conditions that raise substantial doubt about its ability to continue as a going concern.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue—3.2
Net income-8.1-7.7
EPS (diluted, $ a share)$-1.94$-9.86

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CRIS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Curis Inc: key numbers

Share price
$0.4358Close, Nov 16
Market cap
$4.15M
Shares outstanding
9.51MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Curis Inc

All →
4:07 PM ET 8-K
Financial Results

Curis Financial Results

Curis reported financial results for the third quarter of 2026 and provided an operational update on its TakeAim CLL and TakeAim Lymphoma clinical trials. The company highlighted progress in combining emavusertib with BTK inhibitors for the treatment of CLL and PCNSL, with initial data from the TakeAim CLL study expected in December 2026.

Term
Q3 2026

“The excitement among clinicians and patients reflects the clear unmet need in both CLL and PCNSL, where emavusertib has the potential to change the treatment landscape when combined with approved BTK inhibitors.”

James Dentzer, Chief Executive Officer of Curis
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Curis Nasdaq/NYSE Compliance Notice

Curis, Inc. received a delisting determination letter from Nasdaq on November 2, 2026, because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. Due to a previous 1-for-20 reverse stock split in July 2026 and an existing Panel Monitor, the company is not eligible for a standard compliance period and faces immediate delisting risk. The company intends to appeal the decision to a Nasdaq Hearings Panel to stay the delisting process.

Counterparty
Nasdaq
4:31 PM ET 8-K
Capital Raise

Curis Capital Raise of $8.5M

Curis, Inc. entered into a securities purchase agreement to raise approximately $8.5 million through the sale of 16,666,680 shares of common stock (or pre-funded warrants) and accompanying common warrants at a combined price of $0.51 per share. The company intends to use the proceeds to fund research and development activities, specifically to support operations through its initial Chronic Lymphocytic Leukemia (CLL) data readout expected in December 2026.

Value
$8.5M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.